Actelion to host Conference Call / Audiocast on SERAPHIN Study Results

Mon Apr 30, 2012 1:06am EDT

* Reuters is not responsible for the content in this press release.

Actelion Pharmaceuticals Ltd / Actelion to host Conference Call / Audiocast on SERAPHIN Study Results . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.

Dear member of the investment community,

Actelion Ltd will host a Conference Call / Audiocast on the positive SERAPHIN Study Results today, on Monday, 30 April 2012, at 14.00 CET / 13.00 BST / 08.00 a.m. EST.

The company announced today that its endothelin receptor antagonist, macitentan met the primary endpoint in the pivotal Phase III outcome study in patients with pulmonary arterial hypertension.

Date/Time:

30 April 2012 14.00  - 15.00 hrs Basel (CET)
13.00  - 14.00 hrs UK (BST)
08.00  - 09.00 a.m. US (EST)

Conference Call Connect #:

Dial-in participants should start calling the number below 10-15 minutes before the conference is due to start.

Dial: Europe: +41 (0)44 580 00 74
UK: +44 (0)203 367 94 53
US: +1 866 907 59 23

Participant's mode:
Listen-Only with possibility to open individual lines during Q&A session. Participants will be asked for their Name and Company.

Audiocast Replay:

Audiocast participants should visit the Actelion website www.actelion.com 10-15 minutes before the conference is due to start.


Participant's mode:
Listen only

Audiocast Access:

The archived Investor Audiocast will be available for replay through http://www.actelion.com approximately 60 minutes after the call has ended.

For further information please contact:

Roland Haefeli
Senior Vice President, Head of Investor Relations & Public Affairs                     
+41 61 565 62 62
+1 646 737 49 72
http://www.actelion.com





This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: Actelion Pharmaceuticals Ltd via Thomson Reuters ONE

HUG#1607162

--- End of Message ---

Actelion Pharmaceuticals Ltd
Gewerbestrasse 16 Allschwil Switzerland

ISIN: CH0010532478;


Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.